Cancer Drug Kadcyla Must Be Called By Full Name, FDA Says

Law360, New York (May 6, 2013, 4:31 PM EDT) -- The U.S. Food and Drug Administration on Monday urged health care professionals and publications to use the full generic name of Genentech Inc.’s breast cancer treatment Kadcyla when referring to the drug, saying use of a truncated name could lead to harmful confusion with another treatment.

According to the regulator’s drug safety communication, a number of drug information content publishers and reference databases had failed to use the FDA-approved nonproprietary name for Kadcyla — ado-trastuzumab emtansine — when referring to the drug.

Instead, they had been...
To view the full article, register now.